Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 62 % of short-term debt in 2025; threshold 65 %.
-
Shrinking team NBB
FTE fell two years in a row, from 19.3 to 8.9.
-
Busy address KBO
21 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL from Gent, company number BE0475471036, closed financial year 2025 with a result of € 615,041 after tax. For that financial year BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL recorded a gross margin of € 1.4 million and equity of € 1.2 million. Compared with financial year 2024, the result moved from € 156,990 to € 615,041. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on October 6, 2026.
€ 1.2 million
▲ 105% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 615,041
▲ 292% vs 2024
Profit after tax over the fiscal year.
€ 3,920
▼ 98% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 701,783.
People and assets in 2025
8.9
▼ 5.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 690,926
▼ 38% vs 2024
€ 77,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 250,000
Loans from banks and other lenders, long and short.
€ 1.2 million
▼ 37% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 85,256
▼ 43% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 1,801,167 | € 1,706,178 | € 1,395,393 | € 1,388,612 | |
| Profit after taxes | € 291,274 | € 65,528 | € 156,990 | € 615,041 | ▲ 292% |
| Equity | € 364,224 | € 429,752 | € 586,742 | € 1,201,783 | ▲ 105% |
| Total debts | € 2,264,221 | € 2,903,295 | € 4,260,781 | € 2,490,404 | ▼ 42% |
| Cash | € 250,234 | € 233,521 | € 187,625 | € 3,920 | ▼ 98% |
| Retained profit | € -135,776 | € -70,248 | € 86,742 | € 701,783 | ▲ € 615,041 |
| Bank debt | € 250,000 | € 250,000 | € 250,000 | € 250,000 | |
| Balance sheet total | € 2,628,445 | € 3,333,047 | € 4,847,523 | € 3,692,187 | ▼ 24% |
| Employees (FTE) | 19.9 | 19.3 | 14.6 | 8.9 | ▼ 5.7 |
Key figures of BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL?
What happened at BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 615,041 (▲ 292% vs 2024). filed late Source: NBB ↗
- A.I.P. NV became a director. NBB
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 291,274 profit in 2022 to € 615,041 profit in 2025.
Paid € 1,940 in corporate taxes since 2022.
Best year ever: 2025, with € 615,041 profit.
On average € 156,000 of value added per employee in 2025.
Management
The stake of Advanced incubation platform comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROLBehind BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL is A.I.P. NV. The shares are held by Advanced incubation platform (91.6%).
Directors
According to the 2025 annual accounts
Director · represented by Hugo Van Heuverswyn
since 2020
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rijvisschestraat 118 box 1
9052 Gent
Klaartestraat 16
9052 Gent
Active since 11 September 2001
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 21 companies are registered at this address.
All companies at this address →Advanced incubation platform same network
€ 834,703 gross margin · 2025
STAPLES BELGIUM
€ 676,401 gross margin · 2025
GROUP AIP
INTEGRA CAPITAL PARTNERS
€ 316,495 gross margin · 2025
INTEGRA FUND PRIVAK
+16 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0475.471.036
- VAT number
- BE 0475.471.036
- Registered office
- Rijvisschestraat 118 bus 1, 9052 Gent
- Names & denominations
- BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL · BIOMARIC
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 13 August 2001
- Peppol
- Active · Active since 31 Oct 2023
- Activities · NACE
Medische laboratoria
Activiteiten van medische beeldvorming en medische laboratoria
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van medische laboratoria
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied